MktsMarkets

UroGen Pharma Ltd.
NASDAQ: URGNKey statistics
URGN News
Stories mentioning URGN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 50,959 | 37,837 | 27,482 | 24,215 | 20,254 | 24,565 | 25,204 | 21,848 |
| Cost of Goods Sold | 4,139 | 3,289 | 3,278 | 3,550 | 2,330 | 2,471 | 2,453 | 2,229 |
| Gross Profit | 46,820 | 34,548 | 24,204 | 20,665 | 17,924 | 22,094 | 22,751 | 19,619 |
| Operating Expenses | ||||||||
| Research & Development | 15,597 | 14,314 | 14,008 | 18,914 | 19,871 | 14,894 | 11,355 | 15,402 |
| Sales General & Admin | 51,486 | 39,349 | 37,582 | 43,199 | 34,967 | 34,858 | 28,941 | 30,056 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (20,263) | (19,115) | (27,386) | (41,448) | (36,914) | (27,658) | (17,545) | (25,839) |
| Interest Income | 931.00 | 908.00 | 1,176 | 1,677 | 2,204 | 2,812 | 2,757 | 1,534 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (28,346) | (26,639) | (34,401) | (48,925) | (43,451) | (34,863) | (23,582) | (33,365) |
| Tax Provision | (4,772) | (275.00) | (1,054) | 1,015 | 392.00 | 2,649 | 91.00 | 38.00 |
| Net Income (Loss) | (23,574) | (26,364) | (33,347) | (49,940) | (43,843) | (37,512) | (23,673) | (33,403) |
| Earnings Per Share (Basic) | (0.47) | (0.55) | (0.69) | (1.05) | (0.92) | (0.80) | (0.51) | (0.82) |
| Earnings Per Share (Diluted) | ||||||||
| Weighted Average Shares Outstanding (Basic) | 50,183 | 48,116 | 48,057 | 47,740 | 47,422 | 47,031 | 46,780 | 40,501 |
| Weighted Average Shares Outstanding (Diluted) | ||||||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About URGN
UroGen Pharma Ltd. (NASDAQ: URGN) is a stock listed on the Nasdaq Stock Market under the ticker symbol URGN. It last traded at $34.49 (Oct 23, 2026, 4:00 PM ET), down 1.9% on the day. That gives UroGen Pharma a market capitalisation of $1.7B.
Over the past 52 weeks URGN has traded between $16.50 and $50.81.
Revenue for the quarter ended Mar 31, 2026 was $51.0M; a net loss of $23.6M. Revenue was up 152% from $20.3M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $51.0M | -$23.6M | -46.3% |
| Dec 31, 2025 | $37.8M | -$26.4M | -69.7% |
| Sep 30, 2025 | $27.5M | -$33.3M | -121.3% |
| Jun 30, 2025 | $24.2M | -$49.9M | -206.2% |
From UroGen Pharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…